1. Niederhuber JE, Brennan MF, Menck HR. The National Cancer Data Base report on pancreatic cancer. Cancer 1995;76:1671–1677.
3. Lee WJ. Epidemiology and risk factors in pancreatic cancer. Korean J Hepatobiliary Pancreat Surg 2004;8:61–68.
4. Holly EA, Chaliha I, Bracci PM, Gautam M. Signs and symptoms of pancreatic cancer: a population-based casecontrol study in the San Francisco Bay area. Clin Gastroenterol Hepatol 2004;2:510–517.
5. Fargnoli R, Fusi I. Computerized tomography of pancreatic tumors. Tumori 1999;85(1 Suppl 1):S3–5.
6. Simon B, Printz H. Epidemiological trends in pancreatic neoplasias. Dig Dis 2001;19:6–14.
7. Lowenfels AB, Maisonneuve P. Epidemiology and risk factors for pancreatic cancer. Best Pract Res Clin Gastroenterol 2006;20:197–209.
8. Lowenfels AB, Maisonneuve P, Cavallini G, et al. Pancreatitis and the risk of pancreatic cancer: International Pancreatitis Study Group. N Engl J Med 1993;328:1433–1437.
9. Niederau C, Grendell JH. Diagnosis of pancreatic carcinoma: imaging techniques and tumor markers. Pancreas 1992;7:66–86.
10. Feldman M, Friedman LS, Brandt LJ. Sleisenger and Fordtran's Gastrointestinal and Liver Disease. 8th ed. Philadelphia: Saunders, 2006.
11. Frederick L, Greene D, Irvin D, et al. AJCC Cancer Staging Manual. 8th ed. New york: Springer, 2002.
12. Talamini G, Bassi C, Falconi M, et al. Early detection of pancreatic cancer following the diagnosis of chronic pancreatitis. Digestion 1999;60:554–561.
15. Iordache S, Săftoiu A, Cazacu S, et al. Endoscopic ultrasound approach of pancreatic cancer in chronic pancreatitis patients in a tertiary referral centre. J Gastrointestin Liver Dis 2008;17:279–284.
16. Song SY. Etiology and carcinogenesis of pancreatic ductal adenocarcinoma. Korean J Gastroenterol 2008;51:71–83.
17. Gemmel C, Eickhoff A, Helmstädter L, Riemann JF. Pancreatic cancer screening: state of the art. Expert Rev Gastroenterol Hepatol 2009;3:89–96.
18. De Icaza E, López-Cervantes M, Arredondo A, Robles-Díaz G. Likelihood ratios of clinical, laboratory and image data of pancreatic cancer: Bayesian approach. J Eval Clin Pract 2009;15:62–68.
19. Wang F, Gupta S, Holly EA. Diabetes mellitus and pancreatic cancer in a population-based case-control study in the San Francisco Bay Area, California. Cancer Epidemiol Biomarkers Prev 2006;15:1458–1463.
20. Gullo L, Tomassetti P, Migliori M, Casadei R, Marrano D. Do early symptoms of pancreatic cancer exist that can allow an earlier diagnosis? Pancreas 2001;22:210–213.
21. Klapman J, Malafa MP. Early detection of pancreatic cancer: why, who, and how to screen. Cancer Control 2008;15:280–287.
22. Bedi MM, Gandhi MD, Jacob G, Lekha V, Venugopal A, Ramesh H. CA 19-9 to differentiate benign and malignant masses in chronic pancreatitis: is there any benefit? Indian J Gastroenterol 2009;28:24–27.
23. Peterli R, Meyer-Wyss B, Herzog U, Tondelli P. CA19-9 has no value as a tumor marker in obstructive jaundice. Schweiz Med Wochenschr 1999;129:77–79.
24. Korean Society of Abdominal Radiology. Abdominal Radiology. 2nd ed. Seoul: Ilchokak, 2006.
25. Dianxu F, Shengdao Z, Tianquan H, et al. A prospective study of detection of pancreatic carcinoma by combined plasma K-ras mutations and serum CA19-9 analysis. Pancreas 2002;25:336–341.
26. Salek C, Benesova L, Zavoral M, et al. Evaluation of clinical relevance of examining K-ras, p16 and p53 mutations along with allelic losses at 9p and 18q in EUS-guided fine needle aspiration samples of patients with chronic pancreatitis and pancreatic cancer. World J Gastroenterol 2007;13:3714–3720.